Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have synthesized cucurbitacin B derivatives acting as NF-κB activation inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Chengdu Scimount Pharmatech Co. Ltd. has disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune, inflammatory, bone, cardiovascular, metabolic, neurological and respiratory disorders.
Researchers from Fudan University and affiliated organizations have reported the discovery of dual inhibitors of histone deacetylase (HDAC) and tubulin polymerization as potential anticancer agents.
Syndax Pharmaceuticals Inc. is gearing up for a U.S. FDA filing by the end of 2023 on the back of positive data from a pivotal phase I/II study testing menin inhibitor revumenib in adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute myeloid leukemia and acute lymphoid leukemia.
U.S. researchers reported seeking patent protection for methods to neutralize circulating tumor cells (CTCs) during hemodialysis to prevent cancer metastasis and reduce cancer-related deaths.
Shanghai Yingli Pharmaceutical Co. Ltd. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Researchers from Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have synthesized son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous syndrome and Noonan syndrome.
Shenzhen Targetrx Biotechnology Co. Ltd. has disclosed cycloalkyl or heterocyclyl substituted heteroaryl compounds acting as Bruton tyrosine kinase (BTK) and BTK (C481S mutant) inhibitors reported to be useful for the treatment of cancer, inflammation, allergy and autoimmune disease.
Researchers from Zhengzhou University have reported the discovery of lysine-specific histone demethylase 1A (LSD1) inhibitors as potential immune response enhancers for the treatment of gastric cancer.
The calcineurin inhibitor tacrolimus is an immunosuppressive drug frequently used to prevent transplant rejection in solid organ transplant patients. Tacrolimus acts by suppressing T-cell activity within and around the transplanted organ. However, this drug also inhibits T-cell function in the skin, contributing to a high incidence of skin cancer among transplant recipients.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
